DNA X (SONM) Fundamental Analysis: Revenue, Earnings & Valuation

0.21 / 10

Underperform

Fundamental rating is Underperform with a 0.2/10 quality score. Positive signs include low long‑term debt to working capital and modest net‑income‑to‑revenue, while profit‑to‑MV, cash‑up and PB‑ROE are weak, indicating overall fragile fundamentals.

Analysis Checks(6/10)

Revenue-MV

Value2.54

Score0/3

Weight116.08%

1M Return-11.40%

Inventory turnover ratio

Value3.06

Score3/3

Weight-91.27%

1M Return5.75%

Profit-MV

Value0.40

Score1/3

Weight39.91%

1M Return-3.35%

Net income-Revenue

Value-0.15

Score2/3

Weight-23.29%

1M Return2.05%

PB-ROE

Value-0.94

Score0/3

Weight87.39%

1M Return-13.02%

Rate of return on total assets (%)

Value-26.03

Score3/3

Weight-49.86%

1M Return3.98%

Cash-UP

Value-0.01

Score1/3

Weight76.01%

1M Return-9.22%

Long-term debt to working capital ratio (%)

Value26.96

Score2/3

Weight-4.85%

1M Return0.32%

Annualized return on total assets (%)

Value-34.71

Score3/3

Weight-49.86%

1M Return3.98%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-0.25%

1M Return0.02%

Is SONM undervalued or overvalued?

SONM scores 0.21/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -56.48% net margin, -0.17 P/E ratio, -7.71 P/B ratio, and -115.68% earnings growth, these metrics solidify its Underperform investment rating.